Skip to main content

Part of the book series: Developments in Cardiovascular Medicine ((DICM,volume 100))

  • 38 Accesses

Abstract

The principles of experiment design for studies to assess the effect of therapy on acute myocardial ischemic injury are described, including ways in which such studies should be controlled for those factors which contribute to variation in infarct size. In the open-chest anesthetized dog, 90% of variation in infarct size is due to differences in the: 1) size of the vascular area at risk of infarction and, 2) volume of collateral arterial flow to this region. Although damaged by ischemia, myocytes do not die if the myocardium is reperfused with arterial blood less than 15 minutes after the onset. However, virtually all severely and moderately ischemic myocytes will be dead after six hours of ischemia have passed. The damaged myocytes die first in the subendocardium and then in a wavefront which extends out to and may include the subepicardial myocardium. In most hearts, some myocytes still are salvageable by reperfusion after being subjected to episodes of ischemia of as long as three hours.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Braunwald, E. and Sobel, B.E. In: Heart Disease. A Textbook of Cardiovascular Medicine (Ed. E. Braunwald), W.B. Saunders, Co., Philadelphia, 1988, pp. 1191–1221.

    Google Scholar 

  2. Jennings, R.B., Reimer, K.A., and Steenbergen, C., Jr. J. Mol. & Cell Cardiol. 18:769–780, 1986.

    Article  CAS  Google Scholar 

  3. Reimer, K.A. and Jennings, R.B. Lab. Invest. 40:633–644, 1979.

    PubMed  CAS  Google Scholar 

  4. Reimer, K.A. and Jennings, R.B. Circulation 60:866–876, 1979.

    PubMed  CAS  Google Scholar 

  5. Jugdutt, B.I., Hutchins, G.M., Bulkley, B.H. and Becker, L.C. Circulation 60:1141–1150, 1979.

    PubMed  CAS  Google Scholar 

  6. Murdock, R.H., Jr. and Cobb, F.R. Circ. Res. 47:701,-709, 1980.

    PubMed  Google Scholar 

  7. Reimer, K.A., Jennings, R.B., Cobb, F.R., Murdock, R.H., Greenfield, J.C., Jr., Becker, L.C, Bulkley, B.H., Hutchins, G.M., Schwartz, R.P., Jr., Bailey, K.R., and Passamani, E.R. Circ. Res. 56:651–665, 1985.

    PubMed  CAS  Google Scholar 

  8. Menick, F.J., White, F.C. and Bloor, CM. Am. Heart J. 82:503–510, 1971.

    Article  PubMed  CAS  Google Scholar 

  9. Schaper, W. In: Therapeutic Approaches to Myocardial Infarct Size Limitation (Eds. D.J. Hearse and D.M. Yellon), Raven Press, New York, 1984, pp. 79–90.

    Google Scholar 

  10. Jennings, R.B. and Reimer, K.A.: In: Enzymes in Cardiology: Diagnosis and Research (Eds. D.J Hearse and J. de Leiris), John Wiley & Sons, New York., 1979, p. 21–58.

    Google Scholar 

  11. Hugenholtz, P.G. J. Am. Coll. Cardiol. 9:1375–1384, 1987.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Kluwer Academic Publishers

About this chapter

Cite this chapter

Jennings, R.B., Reimer, K.A. (1989). Measurement of Infarct Size: Effect of Reperfusion with Arterial Blood. In: Morganroth, J., Moore, E.N. (eds) Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents. Developments in Cardiovascular Medicine, vol 100. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1605-3_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-1605-3_1

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-8888-6

  • Online ISBN: 978-1-4613-1605-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics